The Children’s Tumor Foundation hosted an informative webinar from NFlection Therapeutics to share results from the Phase 2b Study of NFX‑179 Topical Gel in the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 (NF1). NFX-179 is a topical (on the skin) treatment for cutaneous neurofibromas (cNF), which are tumors that grow in the skin or right underneath the skin and result in severe, disfiguring bumps on the skin.
Recorded live on January 18, 2024, Kavita Sarin, MD, PhD, Associate Professor of Dermatology at Stanford University School of Medicine, gave an informative summary of the clinical trial results. Following the presentation, the NFlection Chief Executive Officer William Hodder and Chief Operating Officer Gern Kochendoerfer, along with Dr. Sarin, answered attendees’ questions and provided additional information.
Last year, the Children’s Tumor Foundation entered a new phase in its strategic NF research model by announcing a significant impact investment in this Phase 2b clinical trial at NFlection Therapeutics, a biotechnology company focused on the discovery and development of effective, targeted therapies for rare diseases. CTF’s investment strategy in NF drug development is a diversified portfolio approach to tackling all forms of NF, from early-stage investments in young investigators, open data collaboratives such as Synodos. This first-in-its-history impact investment further establishes CTF as a co-investor with pharma/biotech in innovative NF research, expanding opportunities to increase the NF drug development pipeline.
Read the NFlection press release here.
The recording of the January 18, 2024 webinar is below. To enable Closed Captioning, click the CC button.
